Johnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care*

Irvine, CA – October 10, 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC., introduced today the Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias (CORE-VA) during the International Symposium on Ventricular Arrhythmias in Philadelphia, PA. The prospective, multicenter registry is designed to capture contemporary practice patterns in ventricular arrhythmia, including ventricular tachycardia (VT), ablation and generate high-quality real-world evidence.

“Real-world standard-of-care registries are essential for refining techniques, guiding training and expanding patient access,” said Francis E. Marchlinski¹, M.D., Director of Electrophysiology, University of Pennsylvania Health Care System, and CORE-VA Steering Committee Co-Chair. “CORE-VA could illuminate how we can simplify procedures, further identify and avoid risks, and improve access and outcomes for ventricular arrhythmia patients.”

VT is a rapid heart rhythm that starts in the lower chamber of the heart and is a form of ventricular arrhythmia.ⁱ Together with ventricular fibrillation, VT drives the majority of sudden cardiac deaths, resulting in about 300,000 fatalities annually in the United States.ⁱⁱ Since VT ablation is a highly complex procedure, it is typically performed by skilled electrophysiologists with advanced treatment strategies.^iii,iv CORE-VA aims to become the largest data repository of ventricular mapping and ablation workflows, technologies and patient outcomes.

“CORE-VA is another example of Johnson & Johnson’s commitment to building rigorous clinical and scientific evidence that shapes the future of arrhythmia care,” said Jennifer Currin Ph.D., Vice President, Scientific Affairs, Electrophysiology, Johnson & Johnson MedTech. “As new technologies are introduced and adopted into clinical practice, this registry will enable us to rapidly collect and analyze real-world data, helping to benchmark outcomes against existing technologies and guide best practices. The insights gained through this collaborative effort have the potential to inform clinical standards, training initiatives and future advancements in this complex arrythmia field.”

* Only THERMOCOOL™ Navigation Catheters except for THERMOCOOL™ SF Catheters and THERMOCOOL SMARTTOUCH™ SF Catheters, are indicated for the treatment of recurrent drug/device refractory sustained monomorphic ventricular tachycardia (VT) due to prior myocardial infarction (MI) in adults.

Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_TAPE_407218

Footnotes
¹ Dr. Marchlinski serves as a consultant for Johnson & Johnson but was not compensated for this announcement.

ⁱ Mayo Clinic Staff. Ventricular tachycardia. Mayo Clinic. Updated March 6, 2024. Accessed October 2, 2025. https://www.mayoclinic.org/diseases-conditions/ventricular-tachycardia/symptoms-causes/syc-20355138

ⁱⁱ Foth C, Gangwani MK, Ahmed I, Alvey H. Ventricular Tachycardia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Last Update: July 30, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532954/.

ⁱⁱⁱ Nof E, Stevenson WG, John RM. Catheter Ablation for Ventricular Arrhythmias. Arrhythm Electrophysiol Rev. 2013 Apr;2(1):45-52. doi: 10.15420/aer.2013.2.1.45. PMID: 26835040; PMCID: PMC4711562.

^iv Falzone PV, Vazquez-Calvo S, Roca-Luque I. Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives. Curr Heart Fail Rep. 2024 Jun;21(3):174-185. doi: 10.1007/s11897-024-00656-y. Epub 2024 Mar 27. PMID: 38536648.